The UK Fibrodysplasia Ossificans Progressiva (FOP) therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Fibrodysplasia Ossificans Progressiva also known as Myositis Ossificans Progressiva, is a rare genetic disorder in which muscle tissue and connective tissue such as tendons and ligaments are replaced by bone, forming bone outside the skeleton (extra-skeletal or heterotopic bone) which restricts the movement of that part of the body. This disorder most often starts in early childhood and it begins from the shoulders and neck, then it goes down through the rest of the body, as patients get older the bone replaces more and more of soft tissue and its progression vary from person to person.
In the UK there are about 40 individuals. Of an estimated 4000 affected individuals worldwide, there are approximately 900 known patients. This disorder affects both genders and all ethnicities. The prevalence in females with FOP (36 %) was almost fourfold greater than in males. This indicates a point prevalence of 0-61 x 10-6. A significant paternal age effect was evident for these new mutations in the UK.
Market Growth Drivers
The rise in market value can be attributed to the introduction of new treatments and therapies and development in the healthcare expenditure and the government support for the research and development for new and better treatment have fuelled the market growth.
Another market driver could be the rising demand for innovative treatments and cures. The market is also growing as people become more aware of FOP and how to treat it. The government’s assistance for research and development for new and improved treatments may help to boost the market’s growth. Increased healthcare spending will also help the market thrive. The introduction of novel therapies and an increase in cases of FOP are likely to be major drivers of the FOP therapeutics market.
Delay in achieving the correct FOP diagnosis, lack of supporting regional infrastructure to patients and families, and the inability of individuals with the FOP in remote or underserved areas to reach the FOP community are the factors that are hampering the market.